Company
Nipro
Last checked: Nov 19, 2026Source: SEC EDGAR, openFDA and ClinicalTrials.govMethods & limitations
FDA decisions since 2015
17
510(k), De Novo and PMA
Device trials
3
As lead sponsor, any status
Adverse event reports
230
Received Nov 1, 2025 to Nov 19, 2026
Recall records
24
One per recalled product
This company is not on our public-company list, so only this exact name is matched. Naming a company here is not a recommendation of it or of any security.
Financing
From SEC filings.
We found no SEC financing filings under the name Nipro, so its financing is unknown here. That is common for companies based outside the US, for subsidiaries of larger companies, and for companies funded by founders, grants or customers. A company that changed its name can also be missed.
Not in public filings: valuations, share prices and investors' names. Private databases such as PitchBook and Crunchbase estimate these from press releases and surveys.
Investors
5%+ shareholders from SEC Schedule 13D/13G filings since Dec 1, 2024, and SBIR/STTR grants (NIH through Nov 10, 2026, other agencies through 2023). Venture investors in private rounds are not in public filings.
No 5%+ shareholder filings or SBIR grants found under the name Nipro.
Latest FDA decisions
The 8 newest of 17 since 2015.
K260799 · Decided Aug 19, 2026 · 161 days after receipt
Device type: Dialysate Concentrate For Hemodialysis (Liquid Or Powder) (KPO) · GI, Urology & Nephrology
- ELISIO-HX510(k)
K261399 · Decided Jul 28, 2026 · 90 days after receipt
Device type: Hemodialyzer With Expanded Solute Removal Profile (QAX) · GI, Urology & Nephrology
- PRESSONE510(k)
K253047 · Decided Mar 24, 2026 · 183 days after receipt
Device type: Needle, Hypodermic, Single Lumen (FMI) · Hospital Medicine & Nursing
14 more FDA decisions with a free account
Device trials
Trials on ClinicalTrials.gov that list this company as lead sponsor, most recently updated first.
NCT07058909 · 22 participants · Start Sep 8, 2025 · Primary completion Feb 25, 2026
Device: ELISIO™-HX Dialyzer · For: Renal Failure; Acute Renal Failure; Chronic Renal Failure and 2 more
Sites: Norfolk, Virginia
- The Golazo® Peripheral Atherectomy System for a Safe and Effective Atherectomy (GREAT Trial)Recruiting
NCT06321575 · 159 participants (planned) · Start Jun 20, 2024 · Primary completion Nov 2026
Device: Golazo® Peripheral Atherectomy System (Golazo® Peripheral AS) · For: Peripheral Arterial Disease
Sites: Scottsdale, Arizona; Merced, California; Fort Lauderdale, Florida · 20 sites in all
NCT01653808 · 20 participants · Start Apr 2009 · Primary completion Sep 2012
Device: Elisio-210H · For: Chronic Kidney Disease
Sites: Montpellier, France
Reports received
230
Received Nov 1, 2025 to Nov 19, 2026
Malfunction reports
173
75% of reports
Injury reports
52
23% of reports
Death reports
5
2.2% of reports
Adverse event reports received per month
Reports that name this company as manufacturer, by the date FDA received them. The newest month is incomplete.
- Malfunction
- Injury
- Death
- Other
View as table
| Month | Malfunction | Injury | Death | Other |
|---|---|---|---|---|
| Dec 23 | 0 | 2 | 0 | 0 |
| Jan 24 | 0 | 2 | 0 | 0 |
| Feb 24 | 2 | 0 | 3 | 0 |
| Mar 24 | 0 | 0 | 0 | 0 |
| Apr 24 | 2 | 0 | 0 | 0 |
| May 24 | 0 | 0 | 4 | 0 |
| Jun 24 | 5 | 3 | 2 | 0 |
| Jul 24 | 5 | 2 | 0 | 0 |
| Aug 24 | 1 | 0 | 4 | 0 |
| Sep 24 | 0 | 0 | 0 | 0 |
| Oct 24 | 2 | 1 | 0 | 0 |
| Nov 24 | 3 | 2 | 0 | 0 |
| Dec 24 | 18 | 6 | 0 | 0 |
| Jan 25 | 0 | 0 | 0 | 0 |
| Feb 25 | 12 | 1 | 0 | 0 |
| Mar 25 | 6 | 1 | 1 | 0 |
| Apr 25 | 1 | 2 | 0 | 0 |
| May 25 | 12 | 3 | 1 | 0 |
| Jun 25 | 32 | 1 | 0 | 0 |
| Jul 25 | 2 | 2 | 0 | 0 |
| Aug 25 | 2 | 1 | 0 | 0 |
| Sep 25 | 0 | 11 | 0 | 0 |
| Oct 25 | 4 | 7 | 0 | 0 |
| Nov 25 | 3 | 0 | 0 | 0 |
| Dec 25 | 0 | 2 | 0 | 0 |
| Jan 26 | 3 | 0 | 1 | 0 |
| Feb 26 | 1 | 0 | 0 | 0 |
| Mar 26 | 1 | 0 | 0 | 0 |
| Apr 26 | 64 | 2 | 1 | 0 |
| May 26 | 30 | 13 | 1 | 0 |
| Jun 26 | 18 | 20 | 0 | 0 |
| Jul 26 | 18 | 6 | 0 | 0 |
| Aug 26 | 12 | 4 | 0 | 0 |
| Sep 26 | 11 | 1 | 0 | 0 |
| Oct 26 | 12 | 4 | 2 | 0 |
| Nov 26 | 0 | 0 | 0 | 0 |
Device types named most often
Last 12 months, by FDA product code. A company that sells more gets more reports.
7 more in this ranking with a free account
Brand names named most often
Last 12 months, as written on the reports. One product can appear under several spellings.
7 more in this ranking with a free account
Recent recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
- MedicaLyte Liquid Bicarbonate Concentrate REF: BC-100 and BC+201Open, Classified
Z-3133-2026 · Started Aug 5, 2026 · Posted by FDA Sep 10, 2026
Reason given: Hemodialysis concentrates contain high endotoxin levels
Cause as FDA categorized it: Process control · Device type: Dialysate Concentrate For Hemodialysis (Liquid Or Powder) (KPO)
- MedicaLyte Bicarbonate Powder REF: DB+201-2.1(45X) and DB+201-25 (35X, 36.83X, 45X))Open, Classified
Z-3134-2026 · Started Aug 5, 2026 · Posted by FDA Sep 10, 2026
Reason given: Hemodialysis concentrates contain high endotoxin levels
Cause as FDA categorized it: Process control · Device type: Dialysate Concentrate For Hemodialysis (Liquid Or Powder) (KPO)
Z-3135-2026 · Started Aug 5, 2026 · Posted by FDA Sep 10, 2026
Reason given: Hemodialysis concentrates contain high endotoxin levels
Cause as FDA categorized it: Process control · Device type: Dialysate Concentrate For Hemodialysis (Liquid Or Powder) (KPO)
21 more recall records with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.